Scope of report
- The report provides a snapshot of the global therapeutic landscape of Fragile X Syndrome.
- The report assesses Fragile X Syndrome pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report reviews Fragile X Syndrome pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development for Fragile X Syndrome ranging from discovery to pre-registration and undisclosed stages.
Neuren Pharmaceuticals, Addex Pharmaceuticals, Seaside Therapeutics, Ecopia BioSciences, NexGenix Pharmaceuticals, Neuropharm, Merck & Co, Afraxis, Sage Therapeutics, Kareus Therapeutics, Zynerba Pharmaceuticals, Selvita, Hua Medicine, Confluence Pharmaceuticals, Fulcrum Therapeutics, Vencerx Therapeutics, Purdue Pharma, Cortex Pharmaceuticals, XenoPort, Roche, Alcobra, Neurotrope BioScience
Trofinetide, Diazepinomicin, Fenobam, STX 107, KU 046, ZYN 002, AMO 01, Acamprosate, Ganaxolone, Memantine, Gaboxadol, Basimglurant, Arbaclofen, Metadoxine extended-release, Bryostatin, Mavoglurant, ANAVEX 2-73
Format: Microsoft Excel
- Single Use: $300
- Site License: $500
- Global License: $800